Adipotide (FTPP)

Adipotide (FTPP) is a synthetic peptidomimetic research compound engineered as a bifunctional chimeric peptide that combines the cyclic CKGGRAKDC adipose-vasculature homing motif with the D(KLAKLAK)₂ proapoptotic effector domain through a Gly-Gly linker. It is supplied as an investigational laboratory peptide for use in ligand-directed vascular-targeting research, prohibitin/annexin-A2 receptor research, and structure–activity studies on chimeric peptidomimetic design.

Laboratory research studies have positioned adipotide as a reference compound for examining how engineered homing motifs engage the prohibitin/annexin-A2 receptor complex on adipose-vasculature endothelial cells in research models. Research models have investigated its receptor binding kinetics, internalization dynamics, and downstream mitochondrial-membrane research, providing comparative data versus the CKGGRAKDC homing motif alone and other ligand-directed peptidomimetic research compounds (Salameh et al., 2016, JCI Insight).

Beyond receptor pharmacology, adipotide is investigated in cellular and animal research models that explore adipose-vasculature research, endothelial-cell research, prohibitin/annexin-A2/CD36 complex research, and structure–activity research on chimeric peptidomimetic design. The molecule's bifunctional architecture, which combines a ligand-directed homing domain with a mitochondrial-membrane-engaging effector domain through a Gly-Gly linker, is also a frequent subject of structural-design and chimeric-peptide research (Adipotide peptidomimetic annexin research, PubMed).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Ligand-directed peptidomimetic research has investigated engineered chimeric peptides that combine tissue-selective homing motifs with effector domains to support structure–activity research on receptor-mediated tissue-vasculature engagement. The CKGGRAKDC cyclic peptide motif was identified through in vivo phage-display research as a sequence that engages prohibitin and annexin-A2 on the endothelial surface of adipose-vasculature research models.

Adipotide (FTPP) was developed as a synthetic chimeric peptidomimetic by linking the CKGGRAKDC homing motif to the D(KLAKLAK)₂ proapoptotic effector domain through a Gly-Gly spacer. The D-amino-acid stereochemistry of the effector domain confers resistance to enzymatic degradation in research models, while the cyclic CKGGRAKDC motif provides selectivity for the prohibitin/annexin-A2 receptor complex expressed on adipose-vasculature endothelial cells.

This structural design has made adipotide a widely studied reference compound for laboratory investigations of ligand-directed vascular-targeting research, prohibitin/annexin-A2 receptor engagement, and downstream mitochondrial-membrane research in adipose-vasculature endothelial-cell research models. Research interest spans adipose-vasculature research, endothelial-cell research, prohibitin/annexin-A2/CD36 complex research, and structure–activity research on chimeric peptidomimetic design.

1. Prohibitin/Annexin-A2 Receptor Engagement

Adipotide interacts with the prohibitin/annexin-A2 receptor complex on adipose-vasculature endothelial cells in research models. Research models indicate that the cyclic CKGGRAKDC homing motif engages this receptor complex with selectivity over vasculature-endothelial cells in other research-tissue compartments, supporting ligand-directed engagement research.

2. Receptor-Mediated Internalization

Upon receptor binding, adipotide engages receptor-mediated internalization pathways in adipose-vasculature endothelial-cell research models. Downstream, this is associated with intracellular delivery of the D(KLAKLAK)₂ effector domain, which is extensively studied in chimeric peptidomimetic research as an upstream regulator of mitochondrial-membrane research endpoints.

3. Mitochondrial-Membrane Engagement by the D(KLAKLAK)₂ Effector

Laboratory research studies have characterized the D(KLAKLAK)₂ effector domain as engaging mitochondrial-membrane research endpoints in research models, modulating mitochondrial-membrane integrity and downstream caspase-pathway signaling. This engagement is an active area of structure–activity research and is investigated as a defining feature of bifunctional chimeric peptidomimetic design.

4. Prohibitin/Annexin-A2/CD36 Complex Research

Research models have investigated the broader prohibitin/annexin-A2/CD36 trimolecular complex on adipose-vasculature endothelial cells, which engages fatty-acid transport research pathways. Adipotide research has supported mechanistic mapping of this complex in adipose-vasculature research and comparative pharmacology with other ligand-directed peptidomimetic research compounds.

Research Applications

Conclusion

Adipotide (FTPP) represents a structurally engineered chimeric peptidomimetic that has become a central reference compound in ligand-directed vascular-targeting research. Its combination of a cyclic CKGGRAKDC adipose-vasculature homing motif, a D(KLAKLAK)₂ proapoptotic effector domain, and a Gly-Gly spacer makes it a valuable investigational laboratory peptide for studying receptor-mediated internalization, prohibitin/annexin-A2 receptor engagement, and chimeric peptidomimetic structure–activity research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.